14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $0.0060 $169.56 Friday, 27th Jan 2023 GBT stock ended at $68.49. During the day the stock fluctuated 0% from a day low at $68.49 to a day high of $68.49.
90 days $113.65 $133.77
52 weeks $171.20 $133.77

Historical GLOBAL BLOOD THERAPEUTICS prices

Date Open High Low Close Volume
Nov 30, 2016 $19.20 $19.55 $18.91 $19.15 487 592
Nov 29, 2016 $18.15 $18.90 $17.87 $18.65 242 360
Nov 28, 2016 $18.05 $18.50 $17.65 $18.05 410 961
Nov 25, 2016 $17.80 $18.65 $17.50 $18.55 175 562
Nov 23, 2016 $16.90 $17.80 $16.50 $17.70 344 248
Nov 22, 2016 $17.90 $18.10 $17.05 $17.15 400 215
Nov 21, 2016 $17.65 $18.10 $17.40 $17.80 301 086
Nov 18, 2016 $17.60 $17.69 $17.25 $17.55 644 148
Nov 17, 2016 $18.30 $18.77 $17.35 $17.55 404 742
Nov 16, 2016 $19.30 $19.80 $18.10 $18.25 735 360
Nov 15, 2016 $20.40 $20.45 $19.05 $19.50 751 203
Nov 14, 2016 $19.45 $20.80 $19.30 $20.70 495 677
Nov 11, 2016 $18.75 $19.60 $18.40 $19.55 697 705
Nov 10, 2016 $17.70 $19.59 $17.00 $18.75 1 210 586
Nov 09, 2016 $16.75 $17.50 $16.75 $17.50 873 888
Nov 08, 2016 $16.45 $16.95 $16.25 $16.25 295 237
Nov 07, 2016 $17.05 $17.30 $16.20 $16.60 404 000
Nov 04, 2016 $14.80 $16.85 $14.80 $16.70 939 500
Nov 03, 2016 $17.85 $18.25 $15.10 $15.15 1 559 800
Nov 02, 2016 $18.20 $19.00 $17.35 $17.65 1 492 500
Nov 01, 2016 $18.15 $18.75 $17.10 $18.15 1 617 100
Oct 31, 2016 $17.70 $17.70 $16.65 $17.45 395 000
Oct 28, 2016 $18.50 $18.63 $17.60 $17.65 503 200
Oct 27, 2016 $19.55 $19.95 $18.50 $18.60 435 900
Oct 26, 2016 $19.65 $19.92 $19.00 $19.35 580 900
Click to get the best stock tips daily for free!

About GLOBAL BLOOD THERAPEUTICS

GLOBAL BLOOD THERAPEUTICS Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, ... GBT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT